AI-Powered Device Cleared as Noninvasive Skin Cancer Test
The handheld tool, intended for use by primary care physicians, uses spectroscopy and algorithms to evaluate skin lesions for potential cancer in a matter of seconds.
Stay updated with breaking news from Dermasensor Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The handheld tool, intended for use by primary care physicians, uses spectroscopy and algorithms to evaluate skin lesions for potential cancer in a matter of seconds.
Dermasensor Inc. received U.S. FDA clearance for its non-invasive skin cancer evaluation device that provides quantitative identification of all skin cancer types at the point of care and within seconds. The point-and-click device is designed to facilitate detection of skin cancers by primary care physicians (PCPs) and speed the time to diagnosis and treatment.
The FDA has authorized the first artificial intelligence-powered medical device to help doctors detect the most common forms of skin cancer in patients.
The first medical device powered by artificial intelligence and designed to help doctors catch skin cancer has been approved by the U.S. Food and Drug Administration.
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced an...